Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Vaccinex

    Client Virtual Booth

    VACCINEX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Vaccinex
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1895 Mount Hope Avenue, Rochester, NY 14620
    Telephone
    Telephone
    585-271-2700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.vaccinex.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Vaccinex Reports 2023 Financial Results and Provides Corporate Update
    Vaccinex Reports 2023 Financial Results and Provides Corporate Update

    https://www.globenewswire.com/news-release/2024/04/02/2855965/34858/en/Vaccinex-Reports-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    02 Apr 2024
    Share Share
    Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering
    Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering

    https://www.globenewswire.com/news-release/2024/03/27/2853151/34858/en/Vaccinex-Inc-Announces-1-5-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Vaccinex Announces Agreements for Access to ActivMAb® Antigen Virus Technology
    Vaccinex Announces Agreements for Access to ActivMAb® Antigen Virus Technology

    https://www.globenewswire.com//news-release/2024/02/21/2832705/34858/en/Vaccinex-Announces-Multiple-New-Agreements-for-Access-to-ActivMAb-Antigen-Virus-Technology.html

    GLOBENEWSWIRE
    21 Feb 2024
    Share Share
    Vaccinex, Inc. Announces Reverse Stock Split
    Vaccinex, Inc. Announces Reverse Stock Split

    https://www.globenewswire.com//news-release/2024/02/15/2829923/34858/en/Vaccinex-Inc-Announces-Reverse-Stock-Split.html

    GLOBENEWSWIRE
    15 Feb 2024
    Share Share
    Vaccinex Announces Pricing of $3.7 Million PIPE Financing
    Vaccinex Announces Pricing of $3.7 Million PIPE Financing

    https://www.globenewswire.com//news-release/2024/02/07/2825160/34858/en/Vaccinex-Announces-Pricing-of-3-7-Million-PIPE-Financing.html

    GLOBENEWSWIRE
    07 Feb 2024
    Share Share
    Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance
    Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance

    https://www.globenewswire.com//news-release/2023/12/04/2789961/34858/en/Nasdaq-Grants-Vaccinex-Extension-Until-March-4-2024-to-Regain-Compliance-with-Listing-Rule.html

    GLOBENEWSWIRE
    04 Dec 2023
    Share Share
    Vaccinex Reports Third Quarter 2023 Financial Results
    Vaccinex Reports Third Quarter 2023 Financial Results

    https://www.globenewswire.com//news-release/2023/11/13/2778973/34858/en/Vaccinex-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    13 Nov 2023
    Share Share
    Vaccinex Reports Benefit in Analyses from two Phase 2 Studies of Pepinemab
    Vaccinex Reports Benefit in Analyses from two Phase 2 Studies of Pepinemab

    https://www.globenewswire.com//news-release/2023/10/31/2770272/34858/en/Vaccinex-Reports-Clinical-Benefit-in-Interim-Analyses-from-two-Phase-2-Studies-of-Pepinemab-Combination-Treatment-at-Society-for-Immunotherapy-of-Cancer-s-Annual-Meeting.html

    GLOBENEWSWIRE
    31 Oct 2023
    Share Share
    Vaccinex Reports Effect of Pepinemab Treatment in Neurodegenerative Diseases
    Vaccinex Reports Effect of Pepinemab Treatment in Neurodegenerative Diseases

    https://www.globenewswire.com//news-release/2023/10/26/2767669/34858/en/Vaccinex-Reports-Positive-Effect-of-Pepinemab-Treatment-on-New-Biomarker-of-Brain-Inflammation-in-Neurodegenerative-Diseases.html

    GLOBENEWSWIRE
    26 Oct 2023
    Share Share
    Vaccinex™s Next Generation ActivMAb® Technology Published in mAbs
    Vaccinex™s Next Generation ActivMAb® Technology Published in mAbs

    https://www.globenewswire.com//news-release/2023/09/28/2751172/34858/en/Vaccinex-s-Next-Generation-ActivMAb-Technology-Published-in-mAbs-a-Leading-Biotech-Journal-and-Validated-in-OmniAb-Proof-of-Concept-Collaboration.html

    GLOBENEWSWIRE
    28 Sep 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search